SOUTHERN CALIFORNIA ISLET CELL RESOURCES (SCI-ICR) CENTER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 描述(由申请者提供)：在之前的资助期间，南加州胰岛细胞资源中心(SC-ICR)已成为ICR项目中生产率最高的胰岛移植中心之一，同时也为全国范围内ICR批准的项目提供高质量的胰岛。我们还在南加州组建了一个由几个移植中心组成的联盟，并正在努力培训和鉴定它们作为胰岛移植地点的资格，这些地点将使用SC-ICR生产的临床级胰岛。在这些和其他方面，SC-ICR证明了它 发挥真正的胰岛细胞资源中心的作用。 在接下来的一段时间里，我们将把这一成功扩展到改进胰岛细胞的分离、鉴定和存储。在具体目标1中，我们计划通过建造一个完全专用的设施、增加另一个胰岛隔离小组以及增加器官采购活动，将SC-ICR的能力扩大到三倍。在具体目标2中，我们瞄准了几个关键领域，以改善胰岛的恢复和效力。我们正在研究胰岛分离过程中特定时间点的氧气补充，抑制促凋亡途径，以及补充生长因子以最大限度地增加每个器官的胰岛产量。在具体目标3中，我们建立了一个基于最新技术的广泛的胰岛特征分析平台。这些分析侧重于提供胰岛特性和纯度的有效表征，用于确定胰岛潜力的定量功能分析，以及建立一项多中心研究以确定与临床结果相关的分子。在具体目标4中，我们通过开发胰岛存储方法和建立国家胰岛知识库来解决胰岛短缺的问题。我们还着眼于开发新的胰岛素产生细胞来源，而不是身体胰岛的分离。 最后，我们认真对待ICR计划的目的，即促进领先的胰岛隔离中心之间的合作，并与ICR计划的其他成员建立了几项合作努力。作为这一努力的一部分，我们正在努力提供对SC-ICR创建的许多技术、协议、数据库和其他生物信息学资源的访问(具体目标5)。因此，SC-ICR计划将引领胰岛隔离和分布活动的进步，以及提高胰岛产量、质量、质量评估和临床应用的技术开发。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): In the previous funding period, the Southern California Islet Cell Resources (SC-ICR) Center has established itself as one of the most productive islet transplantation centers in ICR program while also providing high quality islets to ICR-approved projects nationwide. We have also assembled a consortium of several transplant centers in Southern California and are working to train and qualify them as islet transplantation sites which will use the clinical-grade islets produced by the SC-ICR. In these and other ways, the SC-ICR has demonstrated that it functions as a true islet cell resource center. In the upcoming period we will extend this success to improving islet cell isolation, characterization, and storage. In Specific Aim 1, we plan to expand the capacity of the SC-ICR up to three folds by constructing a fully dedicated facility, adding another islet isolation team, and increasing organ procurement activities. In Specific Aim 2, we are targeting a few crucial areas for improvement in islet recovery and potency. We are investigating oxygen supplementation at specific points in the islet isolation procedure, inhibition of pro-apoptotic pathways, and supplementation of growth factors to maximize the islet yield from every organ. In Specific Aim 3 we establish an extensive platform of islet characterization assays based on latest technologies. These assays focus on providing validated characterization of islet identity and purity, quantitative functional assays for determining islet potency, and establishment of a multicenter study to identify molecules that are associated with clinical outcome. In Specific Aim 4 we address the problem of islet shortage by development methods for islet storage and establishment of a national islet repository. We are also looking beyond cadaveric islet isolation to development of new sources of insulin-producing cells. Finally, we take seriously the purpose of the ICR program to foster cooperation between leading islet isolation centers and have established several collaborative efforts with other members of the ICR program. As part of this effort, we are working to provide access to the many techniques, protocols, databases, and other bioinformatics resources created by the SC-ICR (Specific Aim 5). Thus, the SC-ICR program is positioned to lead advances in islet isolation and distribution activities and the development of technologies for improving islet yield, quality, quality assessment, and clinical utilization.